Monoamine oxidase inhibitors

Clorgyline analogues with decreased blood-brain barrier permeability address the limitations of first-generation MAOIs by enhancing MAOA inhibition potency and selectivity while minimizing CNS toxicity, effectively treating metastatic prostate cancer with reduced side effects.

WO2024229078A1PCT designated stage expired Publication Date: 2024-11-07ELLISON INSTITUTE LLC +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/027169
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-02
Filing Date
2024-05-01
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

First-generation monoamine oxidase inhibitors (MAOIs) face limitations due to undesirable central nervous system (CNS) toxicity and transient increases in blood pressure, leading to dangerous hypertension, which restricts their clinical use, and there is a need for therapeutic agents that can target MAOI inhibition while minimizing adverse effects.

Method used

Development of clorgyline analogues with decreased blood-brain barrier permeability, achieved through computational analysis and strategic polar substitutions, to maintain or enhance monoamine oxidase A (MAOA) inhibition potency and selectivity while reducing CNS exposure.

Benefits of technology

The clorgyline analogues demonstrate reduced CNS penetration, minimizing side effects while retaining high target enzyme affinity and selectivity, effectively treating cancer, particularly metastatic prostate cancer, with reduced risk of CNS-related adverse effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024027169_07112024_PF_FP_ABST
    Figure US2024027169_07112024_PF_FP_ABST
Patent Text Reader

Abstract

Provided are compounds and pharmaceutical compositions. The compounds may be useful for treating cancer. The compounds may be useful as inhibitors of monoamine oxidase.
Need to check novelty before this filing date? Find Prior Art

Description

WSGR Docket No. 60661-704.601 MONOAMINE OXIDASE INHIBITORS CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 499,684 filed on May 2, 2023, which is incorporated herein by reference. BACKGROUND OF THE INVENTION

[0002] Monoamine oxidase inhibitors (MAO inhibitors or MAOIs) have two serious adverse effects that limit clinical use of first-generation MAOIs: undesirable central nervous system (CNS) toxicity and transient increases in blood pressure, leading to dangerous, even fatal, hypertension. There is a need to develop new therapeutic agents that can target MAOI inhibition while mitigating adverse effects. SUMMARY

[0003] In one aspect, provided herein is a compound, or a pharmaceutically acceptable salt or solvate thereof, or a stereoisomer or mixture of stereoisomers thereof, having the structure of Formula (I):Formula (I) wherein: * denotes R- or S- stereoisomer, or a racemate thereof; R1is hydrogen, -OH, -CN -N(R1a)(R1b), -NHC(=O)R1b, -C(=O)R1a, -SR1a, - OPO3(R1a)(R1b), C1-12alkyl, C1-12hydroxyalkyl, or C1-12haloalkyl; R2is C1-6alkyl, wherein the C1-6alkyl is optionally substituted with -OH, -NH2, -SH, - NHOH, -NHNH2or -O-C1-6alkyl; R3is hydrogen, -OH, or -O-C1-6alkyl; R1ais hydrogen, -OH, -NH2, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; and R1bis hydrogen, -OH, -NH2, -CO-C1-6alkyl, -SO2-C1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C3-12aryl, 3- to 10- membered heterocyclyl, or 3- to 10- membered heteroaryl, wherein when R1is hydrogen, and R3is H, R2is not methyl.

[0004] In some embodiments, R1is hydrogen, -OH, -CN, -N(R1a)(R1b), -NHC(=O)R1b, - C(=O)R1a, C1-12alkyl, C1-12hydroxyalkyl, or C1-12haloalkyl. In some embodiments, R1isWSGR Docket No. 60661-704.601 hydrogen, -OH, -CN, -N(R1a)(R1b), -NHC(=O)R1b, -C(=O)R1a, or C1-6hydroxyalkyl. In some embodiments, R1ais hydrogen, -OH, -NH2, or C1-6alkyl. In some embodiments, R1ais hydrogen or -OH. In some embodiments, R1bis hydrogen, -CO-C1-6alkyl, -SO2-C1-6alkyl, C1-6alkyl, C3-12cycloalkyl, C3-12aryl, 3- to 10- membered heterocyclyl, or 3- to 10- membered heteroaryl. In some embodiments, R1bis hydrogen, C1-3alkyl, -CO-C1-3alkyl, -SO2-C1-3alkyl, or 3- to 10- membered heteroaryl.

[0005] In some embodiments,NHSO2CH3, or -NHC(=O)-pyrazolyl.

[0006] In some embodiments, R2is C1-3alkyl, wherein the C1-3alkyl is optionally substituted with -OH, -NH2, -SH, -NHOH, or -NHNH2. In some embodiments, R2is methyl or -CH2CH2OH. In some embodiments, R3is hydrogen or -OH.

[0007] In some embodiments, the compound is:

[0008] Also provided herein is a pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof described herein, and a pharmaceutically acceptable excipient.WSGR Docket No. 60661-704.601

[0009] Also provided herein is a method of treating cancer in a patient in need thereof, comprising administering to the patient the compound, or pharmaceutically acceptable salt or solvate thereof described herein. In some embodiments, the compound has reduced penetration across the blood- brain barrier as compared to clorgyline using a biodistribution assay. In some embodiments, the compound has a logBB value of less than 0.4. In some embodiments, the compound is a monoamine oxidase inhibitor (MAOI). In some embodiments, the MAOI is a MAOA inhibitor. In some embodiments, the MAOI is a MAOB inhibitor. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is metastatic prostate cancer. In some embodiments, the patient is resistant to another antineoplastic treatment.

[0010] Also provided herein is a method of inhibiting monoamine oxidase (MAO), the method comprising administering the compound, or a pharmaceutically acceptable salt or solvate thereof, described herein, to a patient in need thereof, thereby inhibiting MAO. In some embodiments, the MAO is monoamine oxidase A (MAOA). In some embodiments, the MAO is monoamine oxidase B (MAOB). In some embodiments, the patient has cancer, and inhibition of MAO treats the cancer. In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is metastatic prostate cancer. In some embodiments, the compound has reduced penetration across the blood-brain barrier as compared to clorgyline using the biodistribution assay. In some embodiments, the compound has a logBB value of less than 0.4. BRIEF DESCRIPTION OF THE DRAWINGS

[0011] FIG. 1 is a schematic representation of the monoamine oxidase A (MAOA) signaling network and structural modifications of clorgyline irreversible MAOA inhibitor. DETAILED DESCRIPTION

[0012] MAOIs were first developed as antidepressants in the 1950s. However, two serious adverse effects limited clinical use of first-generation MAOIs: undesirable central nervous system (CNS) toxicity and transient increases in blood pressure leading occasionally to dangerous, even fatal, hypertension. Later studies identified two MAO isoforms (MAOA and MAOB) with distinct tissue distribution and substrate specificities which provided an explanation for the transient hypertension. Non-specific inhibition of MAOA and MAOB in the intestinal mucosa and liver resulted in rapid unopposed absorption of tyramine from certain foods into the circulation. Initial drug development efforts focused on highly-selective MAOIs and non-enteral drug delivery systems as strategies to minimize the risk of adverse effects for these agents and improve therapeutic success. During the last 20 years, selegeline, a MAOB-selective irreversible inhibitor, was approved together with a transcutaneous delivery system to treat major depression and alsoWSGR Docket No. 60661-704.601 as an oral treatment for Parkinson’s disease. Currently, phenelzine (a MAOA / B non-specific inhibitor) is still available for clinical use in the United States, but prescribed only rarely, for patients with atypical and otherwise treatment-resistant forms of major depression.

[0013] Separately, several lines of evidence support a role for monoamine oxidases in disease processes outside the CNS, including carcinogenesis. MAOA is overexpressed in high-grade prostate cancer and is associated with cancer progression, growth, recurrence, and drug resistance. High levels of MAOA expression are seen in other solid tumors including non-small cell lung cancer, pancreatic adenocarcinoma, breast adenocarcinoma, Hodgkin’s lymphoma and glioblastoma. Several studies have shown that MAOA expression is associated with an immunosuppressive microenvironment which can be ameliorated with MAOI inhibition. A phase 2 clinical trial reported the activity of phenelzine in patients with biochemically recurrent prostate cancer. The trial demonstrated an encouraging level of efficacy with prostate specific antigen (PSA) decline ≥50% from baseline in 24% (n=4 / 17) of subjects. However, adverse-effects including dizziness, syncope, and severe hypertension led to early withdrawal in 25% (n=5 / 20) of the enrolled patient-population. MAOA is thus a promising therapeutic target for anti-cancer drug development efforts provided that the risk for CNS-related and other adverse effects associated with the currently available agents can be overcome.

[0014] Using the highly specific, irreversible MAOA inhibitor clorgyline as a scaffold, a suite of clorgyline analogues designed to have decreased blood-brain barrier (BBB) permeability are provided herein. Computational analysis identified optimal substitution sites where introduction of polar substituents have the potential to increase or maintain MAOA selectivity. Additionally, these modifications may reduce CNS exposure as they display a decrease in predicted logBB values (the calculated logarithmic ratio between the equilibrium concentration of the drug in the brain vs blood). LogBB is dependent on various molecular and pharmacokinetic properties such as logP, pKa, and polar surface area. It is generally accepted that BBB penetration is high when LogBB > 0.3, moderate to low when LogBB is 0.3 to -1, and minimal when logBB < -1. Clorgyline derivatives were first synthesized with polar substituents on carbon 5 (Formula (I), position R1) of the phenyl ring to explore potential H-bonding interactions with Serine 209 in the binding pocket (PDB: 2BXS). Additional substitutions were made on the propyl chain and the terminal carbon of the amine.

[0015] In some aspects, provided herein are compounds, or pharmaceutically acceptable salts or solvates thereof, and methods that can decrease CNS penetration to minimize CNS-related side effects while retaining or enhancing MAOA inhibition potency and selectivity.

[0016] In some aspects, using the highly specific, irreversible MAOA inhibitor clorgyline as a scaffold, the present application discloses synthesis of clorgyline analogues designed to haveWSGR Docket No. 60661-704.601 decreased blood brain barrier (BBB) permeability. The present application discloses computational analysis to identify optimal substitution sites where introduction of a polar substituent may increase or, at least, maintain MAOA-specific enzyme inhibition and cytotoxic effect in two prostate cancer cell lines while reducing potential CNS exposure by decreasing logBB (the calculated logarithmic ratio between the equilibrium concentration of the drug in the brain vs in blood plasma).

[0017] In another aspect, provided herein are compounds, or pharmaceutically acceptable salts or solvates thereof, and methods of creating a selective MAOA inhibitor with a logBB value significantly lower than that of clorgyline (0.83) without unduly compromising cancer cell permeability, and while still maintaining high target enzyme affinity and selectivity. In some embodiments, the present application discloses polar substitutions at carbon 5 (Formula (I), position R1) of the phenyl ring to explore potential H-bonding interactions with Serine 209 in the binding site of MAOA. In some embodiments, the present application discloses additional substitutions made on the propyl chain (Formula (I), position R3) and the terminal carbon of the amine (Formula (I), position R2):Formula (I). Compounds

[0018] In some aspects, disclosed herein is a compound, or pharmaceutically acceptable salt or solvate thereof, or a stereoisomer or mixture of stereoisomers thereof, having the structure of Formula (I):Formula (I) wherein: * denotes R- or S- stereoisomer, or a racemate thereof; R1is hydrogen, -OH, -CN -N(R1a)(R1b), -NHC(=O)R1b, -C(=O)R1a, -SR1a, - OPO3(R1a)(R1b), C1-12alkyl, C1-12hydroxyalkyl, or C1-12haloalkyl; R2is C1-6alkyl, wherein the C1-6alkyl is optionally substituted with -OH, -NH2, -SH, - NHOH, -NHNH2or -O-C1-6alkyl; R3is hydrogen, -OH, or -O-C1-6alkyl;WSGR Docket No. 60661-704.601 R1ais hydrogen, -OH, -NH2, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; and R1bis hydrogen, -OH, -NH2, -CO-C1-6alkyl, -SO2-C1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C3-12aryl, 3- to 10- membered heterocyclyl, or 3- to 10- membered heteroaryl, wherein when R1is hydrogen, and R3is H, R2is not methyl.

[0019] In some embodiments, R1is hydrogen, -OH, -CN, -N(R1a)(R1b), -NHC(=O)R1b, - C(=O)R1a, C1-12alkyl, C1-12hydroxyalkyl, or C1-12haloalkyl. In some embodiments, R1is hydrogen, -OH, -CN, -N(R1a)(R1b), -NHC(=O)R1b, -C(=O)R1a, C1-12alkyl, or C1-6hydroxyalkyl. In some embodiments, R1is hydrogen, -OH, -CN, -N(R1a)(R1b), -NHC(=O)R1b, or C1-12alkyl. In some embodiments, R1is hydrogen, -OH, -CN, -N(R1a)(R1b), -NHC(=O)R1b, or C1-6alkyl.

[0020] In some embodiments, R1ais hydrogen, -OH, -NH2, or C1-6alkyl. In some embodiments, R1ais hydrogen, C1-6alkyl, or -OH. In some embodiments, R1ais hydrogen or C1-6alkyl. In some embodiments, R1ais hydrogen or -OH. In some embodiments, R1ais hydrogen. In some embodiments, R1ais -OH.

[0021] In some embodiments, R1bis hydrogen, -CO-C1-6alkyl, -SO2-C1-6alkyl, C1-6alkyl, C3-12cycloalkyl, C3-12aryl, 3- to 10- membered heterocyclyl, or 3- to 10-membered heteroaryl. In some embodiments, R1bis hydrogen, C1-3alkyl, -CO-C1-3alkyl, -SO2-C1-3alkyl, or 3- to 10- membered heteroaryl. In some embodiments, R1bis hydrogen, -CO-C1-3alkyl, -SO2-C1-3alkyl, or pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, and pyrimidinyl. In some embodiments, R1bis hydrogen, -SO2-C1-3alkyl, or pyrrolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, pyridinyl, pyrazinyl, pyridazinyl, and pyrimidinyl.

[0022] In some embodiments, R1is H, -OH, -CN, -CH3, -NH2,-NHC(=O)H, -NHC(=O)CH3, - NHSO2CH3, or -NHC(=O)-pyrazolyl.

[0023] In some embodiments, when R1is hydrogen and R3is H, R2is not methyl.

[0024] In some embodiments, R2is C1-3 alkyl, wherein the C1-3 alkyl is optionally substituted with -OH, -NH2, -SH, -NHOH, or -NHNH2. In some embodiments, R2is methyl, ethyl, or n-propyl, optionally substituted with -OH, -NH2, -SH, -NHOH, or -NHNH2. In some embodiments, R2is - CH3 or -CH2CH2OH.

[0025] In some embodiments, R3is hydrogen, -OH, or -O-C1-6alkyl. In some embodiments, R3is hydrogen or -OH. In some embodiments, R3is hydrogen. In some embodiments, R3is -OH.

[0026] In some embodiments, the compound of Formula (I) is selected from:WSGR Docket No. 60661-704.601Pharmaceutical Compositions

[0027] In some aspects, the present disclosure provides a pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, of Formula (I) and a pharmaceutically acceptable excipient.

[0028] In some embodiments, pharmaceutical compositions can be formulated using one or more physiologically-acceptable carriers comprising excipients and auxiliaries. The formulation can be modified depending upon the route of administration chosen. Pharmaceutical compositions comprising a compound, salt, or conjugate can be manufactured, for example, by lyophilizing the compound, salt or conjugate, mixing, dissolving, emulsifying, encapsulating or entrapping the conjugate. The pharmaceutical compositions can also include the compounds, salts or conjugates in a free-base form or pharmaceutically-acceptable salt form.

[0029] In some embodiments, a compound or salt of Formula (I) may be formulated in any suitable pharmaceutical formulation. A pharmaceutical formulation of the present disclosure typically contains an active ingredient (e.g., compound or salt of Formula (I)), and one or more pharmaceutically acceptable excipients or carriers, including but not limited to: inert solid diluentsWSGR Docket No. 60661-704.601 and fillers, diluents, sterile aqueous solution and various organic solvents, permeation enhancers, antioxidants, solubilizers, and adjuvants.

[0030] In some embodiments, pharmaceutical compositions may also be prepared from a compound or salt of Formula (I) and one or more pharmaceutically acceptable excipients suitable for transdermal, inhalative, sublingual, buccal, rectal, intraosseous, intraocular, intranasal, epidural, or intraspinal administration. Preparations for such pharmaceutical composition are well- known in the art. See, e.g., Anderson, Philip O.; Knoben, James E.; Troutman, William G, eds., Handbook of Clinical Drug Data, Tenth Edition, McGraw-Hill, 2002; Pratt and Taylor, eds., Principles of Drug Action, Third Edition, Churchill Livingston, New York, 1990; Katzung, ed., Basic and Clinical Pharmacology, Ninth Edition, McGraw Hill, 2003; Goodman and Gilman, eds., The Pharmacological Basis of Therapeutics, Tenth Edition, McGraw Hill, 2001; Remingtons Pharmaceutical Sciences, 20th Ed., Lippincott Williams & Wilkins., 2000; Martindale, The Extra Pharmacopoeia, Thirty-Second Edition (The Pharmaceutical Press, London, 1999). Methods

[0031] The compounds described herein can be used in the preparation of medicaments for the prevention or treatment of diseases or conditions. In addition, a method for treating any of the diseases or conditions described herein in a subject in need of such treatment, involves administration of pharmaceutical compositions containing at least one compound described herein, or a pharmaceutically acceptable salt, pharmaceutically acceptable prodrug, or pharmaceutically acceptable solvate thereof, in therapeutically effective amounts to the subject.

[0032] The compositions containing the compound(s) described herein can be administered for therapeutic treatments. In therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition, in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition. Amounts effective for this use will depend on the severity and course of the disease or condition, previous therapy, the patient's health status, weight, and response to the drugs, and the judgment of the treating physician.

[0033] In some aspects, the present disclosure provides methods of treating cancer in a patient in need thereof, comprising administering to the patient a monoamine oxidase inhibitor (MAOI) compound of Formula (I), or pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition disclosed herein.

[0034] In some aspects, the present disclosure provides methods of inhibiting monoamine oxidase (MAO), comprising administering the compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition disclosed herein, thereby inhibiting MAO.WSGR Docket No. 60661-704.601

[0035] In some embodiments, the MAOI compound has reduced penetration across the blood- brain barrier.

[0036] In some embodiments, the MAOI compound has reduced penetration across the blood- brain barrier as compared to clorgyline, wherein the reduction is at least 2-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 3-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 4-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 5-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 6-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 7-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 8-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 9-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 10-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 11-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 12-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 13-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 14-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier as compared to clorgyline, wherein the reduction is at least 15-fold. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier by equal to or greater than about 75% as compared to clorgyline. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier by equal to or greater than about 80%. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier by equal to or greater than about 85%. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier by equal to or greater than about 90%. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier byWSGR Docket No. 60661-704.601 equal to or greater than about 95%. In some embodiments, the MAOI compound has reduced penetration across the blood-brain barrier by equal to or greater than about 100%.

[0037] In some embodiments, the MAOI compound has a logBB value of less than 0.5. In some embodiments, the MAOI compound has a logBB value of less than 0.4. In some embodiments, the MAOI compound has a logBB value of less than 0.35. In some embodiments, the MAOI compound has a logBB value of less than 0.3. In some embodiments, the MAOI compound has a logBB value of less than 0.25. In some embodiments, the MAOI compound has a logBB value of less than 0.2. In some embodiments, the MAOI compound has a logBB value of less than 0.15. In some embodiments, the MAOI compound has a logBB value of less than 0.1. In some embodiments, the MAOI compound has a logBB value of less than 0.05.

[0038] In some embodiments, the MAO is monoamine oxidase A (MAOA).

[0039] In some embodiments, the MAO is monoamine oxidase B (MAOB).

[0040] In some embodiments, the MAOI is a MAOA inhibitor.

[0041] In some embodiments, the MAOI is a MAOB inhibitor.

[0042] In some embodiments, the inhibition of MAO treats cancer after administration to a subject in need thereof.

[0043] In some embodiments, the cancer is prostate cancer. In some embodiments, the cancer is metastatic prostate cancer.

[0044] In some embodiments, the patient is resistant to another antineoplastic treatment. Definitions

[0045] Unless defined otherwise, all terms of art, notations and other technical and scientific terms or terminology used herein are intended to have the same meaning as is commonly understood by one of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms with commonly understood meanings are defined herein for clarity and / or for ready reference, and the inclusion of such definitions herein should not necessarily be construed to represent a substantial difference over what is generally understood in the art.

[0046] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0047] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible subranges as well as individual numerical values within that range. For example, description of a range such as from 1 to 6 should be considered to have specifically disclosed subranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 6, from 3 to 6 etc., as well as individualWSGR Docket No. 60661-704.601 numbers within that range, for example, 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0048] As used in the specification and claims, the singular forms “a”, “an” and “the” include plural references unless the context clearly dictates otherwise. For example, the term “a sample” includes a plurality of samples, including mixtures thereof.

[0049] "Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C1-C15alkyl). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C1-C13alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., C1-C8alkyl). In other embodiments, an alkyl comprises one to five carbon atoms (e.g., C1-C5alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., C1-C4alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C1-C3alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., C1-C2alkyl). In other embodiments, an alkyl comprises one carbon atom (e.g., C1alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15alkyl). In other embodiments, an alkyl comprises five to eight carbon atoms (e.g., C5-C8alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C2-C5alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C3-C5alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl). The alkyl is attached to the rest of the molecule by a single bond. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -ORa, -SRa, -OC(O)- Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -OC(O)-N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)S(O)tRa(where t is 1 or 2), -S(O)tORa(where t is 1 or 2), -S(O)tRa(where t is 1 or 2) and - S(O)tN(Ra)2 (where t is 1 or 2) where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl). In certain embodiments, an optionally substituted alkyl isWSGR Docket No. 60661-704.601 a haloalkyl. In other embodiments, an optionally substituted alkyl is a fluoroalkyl. In other embodiments, an optionally substituted alkyl is a -CF3group.

[0050] "Alkenyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms. In certain embodiments, an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms. The alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, -N(Ra)C(O)ORa, -OC(O)- N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)S(O)tRa(where t is 1 or 2), -S(O)tORa(where t is 1 or 2), -S(O)tRa(where t is 1 or 2) and -S(O)tN(Ra)2(where t is 1 or 2) where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).

[0051] "Alkynyl" refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having from two to twelve carbon atoms. In certain embodiments, an alkynyl comprises two to eight carbon atoms. In other embodiments, an alkynyl comprises two to six carbon atoms. In other embodiments, an alkynyl comprises two to four carbon atoms. The alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -ORa, -SRa, -OC(O)-Ra, -N(Ra)2, -C(O)Ra, -C(O)ORa, -C(O)N(Ra)2, - N(Ra)C(O)ORa, -OC(O)-N(Ra)2, -N(Ra)C(O)Ra, -N(Ra)S(O)tRa(where t is 1 or 2), -S(O)tORa(where t is 1 or 2), -S(O)tRa(where t is 1 or 2) and -S(O)tN(Ra)2(where t is 1 or 2) where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, carbocyclyl (optionally substituted with halogen, hydroxy, methoxy,WSGR Docket No. 60661-704.601 or trifluoromethyl), carbocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl).

[0052] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms. In certain embodiments, a cycloalkyl comprises three to ten carbon atoms. In other embodiments, a cycloalkyl comprises five to seven carbon atoms. The cycloalkyl is attached to the rest of the molecule by a single bond. Cycloalkyl is saturated (i.e., containing single C-C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds). Examples of monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

[0053] "Aryl" refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) S–electron system in accordance with the Hückel theory. The ring system from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene. Unless stated otherwise specifically in the specification, the term "aryl" or the prefix "ar-" (such as in "aralkyl") is meant to include aryl radicals optionally substituted by one or more substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, cyano, nitro, -Rb-ORa, -Rb-OC(O)- -Rb-OC(O)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(O)Ra, -Rb- C(O)ORa, -Rb-C(O)N (Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb- N(Ra)S(O)tRa(where tb a(where t is 1 or 2), -R -S(O)tOR (where t is 1 or 2) and -Rb-S(O)tN(Ra)2(where t is 1 or 2), where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionallyWSGR Docket No. 60661-704.601 substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rbis independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rcis a straight or branched alkylene or alkenylene chain, and where each of the Ra, Rb, or Rcsubstituents is unsubstituted unless otherwise indicated.

[0054] "Heterocyclyl" refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which optionally includes fused or bridged ring systems. The heteroatoms in the heterocyclyl radical are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heterocyclyl radical is partially or fully saturated. The heterocyclyl is attached to the rest of the molecule through any atom of the ring(s). Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, the term "heterocyclyl" is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, - Rb-ORa, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb-OC(O)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(O)Ra, -Rb- C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, -Rb-N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb- N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 1 or 2), -Rb-S(O)tORa(where t is 1 or 2) and -Rb-S(O)tN(Ra)2(where t is 1 or 2), where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionallyWSGR Docket No. 60661-704.601 substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rbis independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rcis a straight or branched alkylene or alkenylene chain, and where each of the Ra, Rb, or Rcsubstituents is unsubstituted unless otherwise indicated.

[0055] "Heteroaryl" refers to a radical derived from a 3- to 18-membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, the heteroaryl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) S–electron system in accordance with the Hückel theory. Heteroaryl includes fused or bridged ring systems. The heteroatom(s) in the heteroaryl radical is optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. The heteroaryl is attached to the rest of the molecule through any atom of the ring(s). Examples of heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H- benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pridinyl, and thiophenyl (i.e.WSGR Docket No. 60661-704.601 thienyl). Unless stated otherwise specifically in the specification, the term "heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from optionally substituted alkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclylalkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, optionally substituted fluoroalkyl, optionally substituted haloalkenyl, optionally substituted haloalkynyl, oxo, thioxo, cyano, nitro, -Rb-ORa, -Rb-OC(O)-Ra, -Rb-OC(O)-ORa, -Rb- OC(O)-N(Ra)2, -Rb-N(Ra)2, -Rb-C(O)Ra, -Rb-C(O)ORa, -Rb-C(O)N(Ra)2, -Rb-O-Rc-C(O)N(Ra)2, - Rb-N(Ra)C(O)ORa, -Rb-N(Ra)C(O)Ra, -Rb-N(Ra)S(O)tRa(where t is 1 or 2), -Rb-S(O)tRa(where t is 1 or 2), -Rb-S(O)tORa(where t is 1 or 2) and -Rb-S(O)tN(Ra)2(where t is 1 or 2), where each Rais independently hydrogen, alkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), fluoroalkyl, cycloalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), cycloalkylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), aralkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heterocyclylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), heteroaryl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), or heteroarylalkyl (optionally substituted with halogen, hydroxy, methoxy, or trifluoromethyl), each Rbis independently a direct bond or a straight or branched alkylene or alkenylene chain, and Rcis a straight or branched alkylene or alkenylene chain, and where each of the Ra, Rb, or Rcsubstituents is unsubstituted unless otherwise indicated.

[0056] EtOAc: ethyl acetate

[0057] CDCl3: deuterated chloroform

[0058] CD3OD: deuterated methanol

[0059] MeCN: acetonitrile

[0060] DMF: dimethylformamide

[0061] HPLC: high performance liquid chromatography

[0062] NMR: nuclear magnetic resonance

[0063] RT: retention time

[0064] rt: room temperature

[0065] DCM: dichloromethane

[0066] TMEDA: tetramethylethylenediamine

[0067] CuCN: copper cyanide

[0068] KCN: potassium cyanide

[0069] ESI: electron spray ionizationWSGR Docket No. 60661-704.601

[0070] TLC: thin layer chromatography

[0071] MS: mass spectrometer

[0072] K2CO3: potassium carbonate

[0073] NaOH: sodium hydroxide

[0074] H2O: water

[0075] EtOH: ethanol

[0076] Cu(BF4)2: copper(II) tetrafluoroborate

[0077] BF3*OEt2: boron trifluoride etherate

[0078] t-BuONO: tert-butyl nitrite

[0079] IPA: isopropyl alcohol

[0080] ADME: absorption, distribution, metabolism, and excretion

[0081] IC50: 50% inhibition constant

[0082] CC50: 50% cytotoxicity concentrations

[0083] SD: standard deviation

[0084] HBD: hydrogen bond donors

[0085] HBA: hydrogen bond acceptors

[0086] Ser: serine

[0087] Glu: glucose EXAMPLES

[0088] The following illustrative examples are representative of embodiments of the compounds, compositions, and methods described herein and are not meant to be limiting in any way. Materials and methods

[0089] Reagents were purchased from Sigma Aldrich, BTC, ACROS, Combi-blocks, or Alfa Assad.

[0090] TLC Silica gel 60 F254plastic plates used for TLC. TLC plates visualized under 254 nm wavelength with UVP light (Model UVLS-28).

[0091] Reaction mixtures were monitored on a Finnigan LCQ Deca XP Max mass spectrometer equipped with an ESI source, both in negative and positive ion mode.

[0092] 1H,13C, and COSY NMR spectra were taken on a Varian Mercury 400, Varian 500, or Varian 600. Proton chemical shifts (δ) were reported in parts per million (ppm) relative to residual CD2HOD in CD3OD (δ 3.34,1H NMR), CHCl3in CDCl3(δ 7.26,1H NMR) or HDO in D2O (δ 4.80,1H NMR). Carbon chemical shifts (δ) were reported in parts per million (ppm) relative to CD3OD (δ 49.00,13C NMR), CDCl3(δ 77.16,13C NMR). NMR spectra processing was performed with MestReNova 14.2.0. Multiplicities are quoted as singlet (s), doublet (d), triplet (t), unresolvedWSGR Docket No. 60661-704.601 multiplet (m), doublet of doublets (dd), doublet of doublet of doublets (ddd), doublet of triplets (dt), triplet of doublets (td), and broad (b).

[0093] High-resolution mass spectrometry (HRMS) data were acquired on a Thermo LTQ- Orbitrap XL in positive ion mode over a m / z range of 100-1,000 at a resolution of 60,000 and a target ion population of 5E+5. ESI voltage was set at 3.75 kV, sheath gas was at 8 (arbitrary) and the capillary temperature was set at 200 °C. The system was operated in a flow-injection analysis (FIA) configuration flowing 30 μL / min of a 50 / 50 water acetonitrile (MeCN) solution modified with 0.1% formic acid (all solvents from Honeywell, Muskegon MI). Samples were diluted (in the flow solvent) to 1 μM and 5 μL manual injections were serially performed. Samples typically eluted over a 0.3 min period with injections spaced at least 1 min apart.

[0094] Compounds were purified by HPLC or automated flash chromatography. HPLC purifications were carried out on a Shimadzu LC-8A equipped with a Shimadzu SPD-20A UV detector (0.5 mm path length), UV detection at 292 nm, using a 10 mm x 250 mm PRP-15 μm silica column eluted at 3-4 mL / min with the indicated solvent. Enantiomers 15 were separated on the same HPLC system using a 4.6 mm x 250 mm Reflect C-Amylose A 5 μm column eluted at 1.5 mL / min. Automated flash chromatography was performed using the Teledyne CombiFlash Rf+ Lumen Flash Chromatography system using a 12 g silica column (flow rate, 30 mL / min) with detection at 254 nm, 280 nm and by ELSD.

[0095] Example 1. Synthesis of Intermediates 2a-2e.

[0096] Clorgyline derivatives were synthesized according to Scheme 1. In the first step, sodium hydroxide was replaced by K2CO3which favored formation of the desired monosubstituted product. The number of dibromopropane equivalents was also increased from 2 to 5, with the same objective. All reactions were carried out under dry N2. ESI MS was used to monitor intermediates and products, with the exception of compound 2c, which was monitored by proton NMR. All compounds were isolated by flash chromatography.WSGR Docket No. 60661-704.601 Scheme 1.

[0097] Specifically, the corresponding phenol starting material, 1,3-dibromopropane (5 eq) and K2CO3(1.5 eq) in anhydrous MeCN (0.11 M) was refluxed under N2, for 2 h, then filtered. The filtrate was evaporated under reduced pressure, leaving the product as a residue which was purified by automated flash chromatography (eluent: hexanes / EtOAc gradient) Solvent was removed under reduced pressure to give final product. 5-(3-Bromopropoxy)-2,4-dichlorophenol (2a)

[0098] White solid.1H NMR (500 MHz, (CDCl3) δ 7.31 (s, 1H), 6.66 (s, 1H), 5.55 (s, IH), 4.13 (t, J = 5.8 Hz, 2H), 3.65 (t, J = 6.4 Hz, 2H), 2.41 – 2.31 (m, 2H). 5-(3-Bromopropoxy)-2,4-dichloroaniline (2b)

[0099] White solid.1H NMR (500 MHz, CD3OD) δ 7.17 (s, 1H), 6.58 (s, 1H), 4.11 (t, J = 5.6 Hz, 2H), 3.67 (t, J = 6.5 Hz, 2H), 2.32 (q, J = 6.0 Hz, 2H). 1-(3-Bromopropoxy)-2,4-dichloro-5-methylbenzene (2c)

[0100] Brown solid.1H NMR (400 MHz, CDCl3) δ 7.34 (s, 1H), 6.81 (s, 1H), 4.14 (t, J = 5.7 Hz, 2H), 3.65 (t, J = 6.3 Hz, 2H), 2.39 – 2.31 (m, 7H). 5-(3-Bromopropoxy)-2,4-dichlorobenzonitrile (2d)

[0101] Yellow solid.1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 7.17 (s, 1H), 4.19 (t, J = 6.1 Hz, 2H), 3.64 (t, J = 6.5 Hz, 2H), 2.39 (h, J = 6.2 Hz, 2H). N-(5-(3-Bromopropoxy)-2,4-dichlorophenyl)acetamide (2e)

[0102] White solid.1H NMR (400 MHz, CD3OD) δ 7.65 (s, 1H), 7.46 (s, 1H), 4.17 (t, J = 5.8 Hz, 2H), 3.66 (t, J = 6.5 Hz, 2H), 2.33 (p, J = 6.2 Hz, 2H), 2.19 (s, 3H).

[0103] Example 2. Synthesis of Intermediates 3a-3e

[0104] The syntheses were carried out according to Scheme 1. K2CO3was omitted and aqueous MeCN as solvent was replaced with anhydrous MeCN to decrease formation of unwantedWSGR Docket No. 60661-704.601 byproducts. The equivalents of propargylamine were increased from 2 to 3 to neutralize HBr formed during the reaction.

[0105] Compounds 2a-2e and propargylamine (3 eq) were dissolved in anhydrous MeCN (0.02 M). The mixture was heated to 78 °C for 2 h under dry N2. After removal of solvent under reduced pressure, the product was purified as indicated for the individual compounds below. 2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)phenol (3a)

[0106] Compound 3a was purified by HPLC with MeOH as the mobile phase. White solid.1H NMR (500 MHz, CDCl3) δ 7.28 (s, 1H), 6.62 (s, 1H), 4.05 (t, J = 6.2 Hz, 2H), 3.43 (d, J = 2.4 Hz, 2H), 2.72 (t, J = 7.1 Hz, 2H), 2.39 (s, 3H), 2.27 (t, J = 2.4 Hz, 1H), 2.02 (p, J = 6.6 Hz, 2H);13C NMR (126 MHz, CDCl3) δ 154.28, 151.10, 129.16, 114.46, 111.13, 101.89, 73.85, 67.23, 51.99, 45.54, 41.60, 26.77. Carbon m is overlapped within the CDCl3solvent peak region 76.764-77.271 ppm; HRMS (+) (m / z): [M+H] calcd. for C13H15Cl2NO2+: 288.0552; found: 288.0549. 2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)aniline (3b)

[0107] Compound 3b was purified by HPLC with MeOH as a mobile phase. White solid.1H NMR (500 MHz, CD3OD): δ 7.14 (s, 1H), 6.53 (s, 1H), 4.01 (t, J = 6.1 Hz, 2H), 3.38 (s, 2H), 2.69 (t, J = 7.5 Hz, 2H), 2.64 (d, J = 2.4 Hz, 1H), 2.35 (s, 3H), 1.97 (p, J = 6.7 Hz, 2H);13CNMR (126 MHz, CD3OD): δ 153.87, 144.00, 128.97, 110.29, 109.77, 100.54, 77.27, 73.70, 66.75, 52.07, 44.75, 40.54, 26.61; HRMS (+) (m / z): [M+H] calcd. For C13H17Cl2N2O2+: 287.0712; found: 287.0708. N-(3-(2,4-Dichloro-5-methylphenoxy)propyl)-N-methylprop-2-yn-1-amine (3c)

[0108] Compound 3c was purified by flash chromatography, hexanes / EtOAc (gradient). Yellow oil.1H NMR (400 MHz, CDCl3) δ 7.32 (s, 1H), 6.80 (s, 1H), 4.06 (t, J = 6.4 Hz, 2H), 3.37 (d, J = 2.4 Hz, 2H), 2.65 (t, J = 7.0 Hz, 2H), 2.34 (s, 3H), 2.32 (s, 3H), 2.22 (d, J = 4.8 Hz, 1H), 2.03 – 1.95 (m, 2H);13C NMR (126 MHz, CDCl3) δ 153.05, 135.39, 129.88, 125.60, 120.76, 115.58,WSGR Docket No. 60661-704.601 73.19, 67.40, 52.05, 45.69, 41.71, 27.16, 20.07; HRMS (+) (m / z): [M+H] calcd. for C14H17Cl2NO+: 286.0759; found: 286.0758. 2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)benzonitrile (3d)

[0109] Compound 3d was purified by HPLC with 40% aq. MeCN / 0.1% formic acid as the mobile phase. Yellow oil.1H NMR (400 MHz, CD3OD) δ 7.77 (s, 1H), 7.59 (s, 1H), 4.28 (t, J = 5.7 Hz, 2H), 4.22 (d, J = 2.6 Hz, 2H), 3.53 – 3.47 (m, 2H), 3.44 (t, J = 3.0 Hz, 1H), 3.04 (s, 3H), 2.34 (t, J = 7.8 Hz, 2H);13C NMR (126 MHz, CD3OD) δ 154.61, 132.38, 130.24, 129.83, 118.97, 116.19, 113.32, 81.32, 68.06, 54.08, 46.38, 40.87, 25.34. Acetone peak at 30.767 ppm. HRMS (+) (m / z): [M+H] calcd. for C+14H14Cl2N2O : 297.0555; found: 297.0554. N-(2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)phenyl)acetamide (3e)

[0110] Compound 3e was purified by flash chromatography, hexanes / EtOAc (gradient). White solid.1H NMR (400 MHz, CD3OD) δ 7.62 (s, 1H), 7.44 (s, 1H), 4.09 (t, J = 6.1 Hz, 2H), 3.39 (s, 2H), 2.71 (t, J = 7.5 Hz, 2H), 2.65 (d, J = 1.2 Hz, 1H), 2.36 (s, 3H), 2.19 (s, 3H), 2.00 (p, J = 6.6 Hz, 2H);13C NMR (126 MHz, CD3OD) δ 170.66, 153.24, 134.11, 129.37, 119.15, 117.52, 110.09, 77.15, 73.81, 67.10, 51.96, 44.75, 40.50, 26.42, 22.09; HRMS (+) (m / z): [M+H] calcd. for C13H17Cl2N2O+: 329.0818; found: 329.0813.

[0111] Example 3. Synthesis of 2,4-dichloro-5-hydroxybenzonitrile (5)

[0112] Diazonium salt 4 was prepared according to Scheme 2. The initial approach for the Sandmeyer cyanation of compound 4 called for the use of dry MeCN. Cyanation and hydrogen abstraction from the solvent are the two pathways of the catalytic Sandmeyer cyanation. In this instance, hydrogen abstraction was the kinetically favored route, resulting in the desired product 5. Deuterated MeCN was substituted for MeCN, which increased the desired product yield.WSGR Docket No. 60661-704.601 Scheme 2Preparation of tert-butyl nitrite

[0113] Tert-butyl alcohol (10.4 g) and sodium nitrite (10.6 g in 62 mL of H2O) were combined and the mixture cooled to 0 °C. Concentrated HCl (12.6 mL) was added dropwise with stirring while keeping the temperature below 6 °C. The mixture was then transferred to a separatory funnel and washed with 100 mL of H2O. The organic phase was washed with 5% sodium bicarbonate (3 X 50 mL), then with H2O (3 x 50 mL) and dried with sodium sulfate. Yellow liquid. 2,4-Dichloro-5-hydroxybenzenediazonium salt (4)

[0114] Amino-2,4-dichlorophenol (250 mg, 1.42 mmol) was dissolved in dry DCM and cooled to 0 °C under dry N2. Boron trifluoride etherate (1 eq, 266.5 μL, 2.13 mmol) and freshly prepared tert-butyl nitrite (1.2 eq, 202.7 μL, 1.7 mmol) were added to the solution. Reaction mixture was stirred at 0 °C for 1 h then warmed to rt. Hexanes (11.5 mL) was added and stirred for 10 min. Precipitate was filtered and washed with DCM; solvent was removed under reduced pressure. No purification was necessary. Orange solid.1H NMR (400 MHz, CD3OD) δ 8.21 (s, 1H), 8.18 (s, 1H). 2,4-Dichloro-5-hydroxybenzonitrile (5)

[0115] Finely ground KCN (2 eq, 130 mg, 2 mmol) was added in 1 mL of deuterated MeCN. Then add dibenzo-18- crown-6 (0.1 eq, 36 mg, 0.1 mmol), CuCN (0.1 eq, 9 mg 0.1 mmol), and Cu(BF4)2(0.1 eq, 24 mg, 0.1 mmol). Reaction mixture was stirred for 2 min at rt under N2. TMEDA (0.1 eq, 11.6 mg, 0.1 mmol) was then added. Reaction mixture stirred for 30 min. Diazonium salt (1 eq, 276 mg 1 mmol) in 1 mL deuterated MeCN was added dropwise. Reaction mixture was stirred for 1 h. 50 mL of ethyl ether was poured into reaction mixture. Reaction mixture was filtered to remove inorganic salts. Solvent was removed under reduced pressure. The product was isolated by automated flash chromatography, hexanes / EtOAc (gradient). Orange solid. 1H NMR (400 MHz, CDCl3) δ 7.62 (s, 1H), 7.24 (s, 1H).

[0116] Example 4. Synthesis of N-(2,4-Dichloro-5-hydroxyphenyl)acetamide (6)

[0117] Compound 6 was synthesized according to Scheme 3.WSGR Docket No. 60661-704.601 Scheme 3

[0118] N-(2,4-Dichloro-5-hydroxyphenyl)acetamide (6): 5-amino-2,4-dichlorophenol (0.85 mmol), acetyl chloride (1.02 mmol), and anhydrous pyridine (6 mL) were stirred at rt overnight and progress was monitored by silica gel TLC (30% EtOAc / hexanes. Purified by automated flash chromatography, hexanes / EtOAc (gradient). White solid.1H NMR (400 MHz, CD3OD) δ 7.50 (s, 1H), 7.36 (s, 1H), 2.16 (s, 3H).

[0119] Example 5. Synthesis of N-(2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy- phenyl)formamide (7), N-(2,4-dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)phenyl)- 1H-pyrazole-3-carboxamide (8), and N-(2,4-dichloro-5-(3-(methyl(prop-2-yn-1- yl)amino)propoxy)phenyl)methanesulfonamide (9)

[0120] Compound 3b was used to synthesize three additional derivatives, as depicted in Scheme 4. Compound 7 was synthesized by adding 3b with a catalytic amount of sodium formate in formic acid and refluxed overnight. The reaction went to completion and no purification was necessary. Compounds 8 and 9 were synthesized by dissolving 3b in anhydrous pyridine containing an excess of the appropriate acid chloride and stirring at rt overnight.WSGR Docket No. 60661-704.601 N-(2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy-phenyl)formamide (7)

[0121] Compound 3b (10 mg, 0.348 mmol), sodium formate (0.2 eq, 47 μg, 6.97 μm), and formic acid (0.5 mL) was refluxed for 12 h. The desired product was extracted with EtOAc and solvent was removed under reduced pressure. No purification was required. Yellow oil.1H NMR (500 MHz, CD3OD) δ 8.38 (s, 1H), 8.07 (s, 1H), 7.45 (s, 1H), 4.10 (t, J = 6.1 Hz, 2H), 3.40 (d, J = 2.4 Hz, 2H), 2.72 (t, J = 7.5 Hz, 2H), 2.66 (s, 1H), 2.37 (s, 3H), 2.01 (p, J = 6.3 Hz, 2H);13C NMR (126 MHz, CD3OD) δ 160.72, 153.36, 133.67, 129.37, 118.18, 114.68, 107.45, 79.08, 73.87, 67.07, 51.95, 44.75, 40.49, 26.40; HRMS (+) (m / z): [M+H] calcd. for C14H16Cl2N2O2+: 315.0661; found: 315.0661. Synthesis of N-(2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)phenyl)-1H- pyrazole-3-carboxamide (8) Preparation of 1H-pyrazole-3-carbonyl chloride

[0122] 1H-Pyrazole-carboxylic acid (1.78 mmol) was dissolved in DCM (8mL). Thionyl chloride (8.9 mmol) and DMF (0.29 mmol) were then added to reaction mixture. The reaction mixture was refluxed under dry N2for 4 h and monitored by ESI MS. The solvent was removed under reduced pressure. Yellow solid.1H NMR (400 MHz, DMSO) δ 8.80 (d, J = 2.9 Hz, 1H), 7.35 (d, J = 2.9 Hz, 1H). N-(2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)phenyl)-1H-pyrazole-3- carboxamide (8)

[0123] Compound 3b (0.23 mmol) was dissolved in anhydrous pyridine (2.5mL). 1H-Pyrazole- 3-carbonyl chloride (0.35 mmol) was then added, and the reaction mixture stirred at rt overnight, with monitored by ESI MS. The solvent was removed under reduced pressure and the residue subjected to automated flash chromatography, 100% EtOAc. Product needed further purification which was done using preparative TLC with EtOAc / hexane. HPLC was performed with 40% MeCN as a mobile phase, 0.1% formic acid. White solid.1HNMR (400 MHz, CD3OD) δ 8.54 (s, 1H), 8.22 (s, 1H), 7.77 (d, J = 2.4 Hz, 1H), 7.49 (s, 1H), 6.87 (d, J = 2.4 Hz, 1H), 4.16 (t, J = 6.1 Hz, 2H), 3.39 (d, J = 2.3 Hz, 2H), 2.72 (t, J = 7.2 Hz, 2H), 2.64 (t, J = 2.4 Hz, 1H), 2.36 (s, 3H), 2.02 (p, J = 6.2 Hz, 1H);13CNMR (126 MHz, CD3OD) δ 153.56, 134.05, 130.34, 129.26, 106.55, 105.28, 76.89, 74.09, 67.06, 52.02, 44.77, 40.46, 26.34; HRMS (+) (m / z): [M+H] calcd. forC17H19Cl2N4O2+: 381.0879; found: 381.0874.N-(2,4-Dichloro-5-(3-(methyl(prop-2-yn-1-yl)amino)propoxy)phenyl)methanesulfonamide (9)

[0124] Compound 3b (0.09 mmol) was dissolved in anhydrous pyridine (2 mL). Methyl sulfonyl chloride (0.39mmol) was added and the reaction mixture stirred overnight at rt. The reaction mixture was diluted in ethyl acetate (20 mL) and washed twice with H2O. The organic layer wasWSGR Docket No. 60661-704.601 dried over sodium sulfate. The solvent was removed under reduced pressure. Compound 9 Purified by automated flash chromatography, hexanes / EtOAc (gradient). White solid.1H NMR (400 MHz, CD3OD) δ 7.49 (s, 1H), 7.24 (s, 1H), 4.11 (t, J = 6.1 Hz, 2H), 3.38 (d, J = 2.3 Hz, 2H), 3.00 (s, 3H), 2.69 (t, J = 7.2 Hz, 2H), 2.63 (t, J = 2.4 Hz, 1H), 2.34 (s, 3H), 1.99 (p, J = 6.1 Hz, 2H);13C NMR (126 MHz, CD3OD) δ 153.63, 133.81, 129.79, 120.29, 118.87, 111.00, 77.23, 73.73, 67.17, 51.86, 44.72, 40.53, 39.20, 26.36; HRMS (+) (m / z): [M+H] calcd. for C13H17Cl2N2O+: 365.0487; found: 365.0484.

[0125] Example 6. Synthesis of N-(Prop-2-ynyl)-N-(2-hydroxyethyl)amine (11) 1-(Prop-2-ynyl)-oxazolidine-2-one (10)

[0126] 2-oxazolidinone (500 mg, 5.74 mmol) was dissolved in dry DMF (12.5 mL) at 0 °C with NaH (2 eq, 275.5 mg, 11.48 mmol). The solution was stirred 1 h. Propargyl bromide (1.5 eq, 1.02 g, 8.61 mmol) diluted in DMF (2.5 mL) was added dropwise for 6 min at 0 °C. After additional h, the reaction mixture was quenched with 250 μL of H2O, and the solvent was completely removed under reduced pressure. After work-up (CHCl3 / H2O; 30 / 10; v / v), the compound was purified by automated flash chromatography, hexanes / EtOAc (gradient). Yellow oil.1H NMR (500 MHz, CDCl3) δ 4.36 (d, J = 15.9 Hz, 3H), 4.09 (d, J = 2.5 Hz, 3H), 3.69 – 3.63 (m, 3H), 2.30 (t, J = 2.5 Hz, 1H). N-(Prop-2-ynyl)-N-(2-hydroxyethyl)amine (11)

[0127] Compound 10 (150 mg, 1.2 mmol) was dissolved in 4M NaOH in H2O / MeOH (1.6 mL). Reaction mixture was heated at 65 °C for 2 h. The crude product was directly treated by a work- up (4x80 mL of CHCl3). The solvent of organic layer was removed under reduced pressure. Yellow oil.1H NMR (400 MHz, CDCl3) δ 3.67 (t, J = 5.2 Hz, 2H), 3.45 (d, J = 2.4 Hz, 2H), 2.86 (t, J = 5.2 Hz, 2H), 2.22 (t, J = 2.4 Hz, 1H).

[0128] Example 7. Synthesis of compounds 12a and 12b

[0129] The corresponding phenol starting material, 1,3-dibromopropane (5eq) and K2CO3(1.5 eq) was refluxed for 3 h in anhydrous MeCN (0.12 M) under N2, then filtered. The reaction mixture was monitored by ESI MS. The filtrate was removed under reduced pressure. See corresponding compound for purification method. 5-(3-Bromopropoxy)-2,4-dichloroaniline (12a)

[0130] No purification was done. Brown solid.1H NMR (400 MHz, CD3OD) δ 7.16 (s, 1H), 6.57 (s, 1H), 4.10 (t, J = 5.8 Hz, 2H), 3.65 (t, J = 6.5 Hz, 2H), 2.31 (q, J = 6.2 Hz, 2H). 1-(3-Bromopropoxy)-2,4-dichlorobenzene (12b)

[0131] Compound 12b was purified by flash chromatography, hexanes / EtOAc (gradient). Pale yellow oil.1H NMR (400 MHz, CDCl3) δ 7.38 – 7.34 (m, 1H), 7.19 (d, J = 8.8 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 4.15 (t, J = 5.8 Hz, 2H), 3.65 (t, J = 6.3 Hz, 2H), 2.36 (p, J = 6.1 Hz, 2H).WSGR Docket No. 60661-704.601

[0132] Example 8. Synthesis of compounds 13a and 13b

[0133] Scheme 5 shows the synthesis of compounds 13a and 13b. Compound 10 was purified by flash chromatography on a silica gel column. Complete removal of the solvent was important for success in the ring opening step. When residual DMF remained in this step, 2-(λ2-azaneyl)ethan- 1-ol was the main product, with no formation of compounds 11, whereas when no DMF was left after solvent evaporation, the reaction went to completion and the product could be obtained without further purification. Compounds 12a and 12b were synthesized similarly. Compounds 13a and 13b were purified by isocratic HPLC utilizing a PRP-1 semi-preparative column eluted with 40% aq. MeCN / 0.1% formic acid.

[0134] Compounds 12 and 11 (2 eq) were dissolved in MeCN (0.03 M) and heated at 65 °C under N2for 4 h. The reaction was monitored by ESI MS. Upon completion, solvent was removed under reduced pressure, and the resulting product was purified as detailed below. 2-((3-(5-Amino-2,4-dichlorophenoxy)propyl)(prop-2-yn-1-yl)amino)ethan-1-ol (13a)

[0135] The product was purified by HPLC in two steps: first, HPLC purification with 50% MeCN:H2O with 0.1% Formic Acid as a mobile phase; and second, HPLC purification with 40% MeCN:H2O with 0.1% Formic Acid as a mobile phase. Yellow oil.1H NMR (400 MHz, CDCl3) δ 7.21 (s, 1H), 6.35 (s, 1H), 4.02 (t, J = 6.2 Hz, 2H), 3.62 (t, J = 5.3 Hz, 2H), 3.47 (d, J = 2.4 Hz, 2H), 2.79 (t, J = 6.9 Hz, 2H), 2.74 (t, J = 5.3 Hz, 3H), 2.21 (t, J = 2.3 Hz, 1H), 1.98 (t, J = 6.6 Hz, 2H);13C NMR (151 MHz, CDCl3) δ 153.80, 142.43, 129.86, 112.03, 110.79, 100.96, 78.08, 73.26,WSGR Docket No. 60661-704.601 66.97, 58.52, 55.19, 49.66, 41.82, 27.04; HRMS (+) (m / z): [M+H] calcd. for C14H18Cl2N2O2+: 317.0818; found: 317.0815. 2-((3-(2,4-Dichlorophenoxy)propyl)(prop-2-yn-1-yl)amino)ethan-1-ol (13b)

[0136] Compound 13b was purified on HPLC with 40% aq. MeCN / 0.1% formic acid as the mobile phase. Yellow oil.1H NMR (400 MHz, CD3OD) δ 7.38 (s, 1H), 7.24 (d, J = 12.7 Hz, 1H), 7.04 (d, J = 11.8 Hz, 2H), 4.10 (t, J = 6.1 Hz, 2H), 3.62 (t, J = 6.6 Hz, 2H), 3.48 (dd, J = 2.6, 1.0 Hz, 2H), 2.78 (t, J = 7.2 Hz, 2H), 2.69 (t, J = 6.6 Hz, 2H), 2.57 (s, 1H), 1.98 (d, J = 6.4 Hz, 2H);13C NMR (126 MHz, CD3OD) δ 153.48, 129.25, 127.47, 125.09, 123.23, 114.22, 77.58, 73.24, 66.98, 59.11, 55.26, 50.01, 41.76, 26.62; HRMS (+) (m / z): [M+H] calcd. for C14H18Cl2N2O2+: 302.0709; found: 302.0708.

[0137] Example 9. Synthesis of 1-(5-amino-2,4-dichlorophenoxy)-3-(methyl(prop-2-yn-1- yl)amino)propan-2-ol (15)

[0138] Scheme 6 shows the synthesis of compounds 15R and 15S. Compound 1b was refluxed in MeCN with epibromohydrin and K2CO3for 5 h to afford compound 14 without the need for further purification. Compound 14 and N-methylpropargylamine were dissolved in ethanol and stirred at rt for 30 min to afford compound 15. Compound 15 was purified by flash chromatography (EtOAc / hexanes) followed by separation of the enantiomers by isocratic HPLC on a Reflect C-Amylose A column eluted with 60% hexanes / IPA. Scheme 62,4-Dichloro-5-(oxiran-2-ylmethoxy)aniline (14)

[0139] 4,6-Dichlorobenzene-1,3-diol (0.56 mmol) was dissolved in MeCN (5 mL). Epibromohydrin (1.12 mmol) and K2CO3(0.84 mmol) were then added, and the solution was set to reflux under dry N2. Reaction progress was monitored by1H NMR and observed to be complete after 5 h. The solvent was removed under reduced pressure, leaving the crude product which contained 20% starting material by1H NMR. White solid.1H NMR (400 MHz, CD3OD) δ 7.40WSGR Docket No. 60661-704.601 (d, J = 2.5 Hz, 1H), 7.25 (dd, J = 8.8, 2.6 Hz, 1H), 7.08 (d, J = 8.9 Hz, 1H), 4.39 (dd, J = 11.4, 2.4 Hz, 1H), 3.95 (dd, J = 11.4, 6.0 Hz, 1H), 3.38-3.34 (m,1H), 2.89 – 2.86 (m, 1H), 2.78 (dd, J = 5.1, 2.6 Hz, 1H). 1-(5-Amino-2,4-dichlorophenoxy)-3-(methyl(prop-2-yn-1-yl)amino)propan-2-ol (15)

[0140] Compound 14 (0.43 mmol) was dissolved in EtOH (2mL). N-methyl propargylamine (2.17 mmol) was then added and the reaction mixture stirred at rt for 30 min. The solvent was removed under reduced pressure and the residual product was purified by flash chromatography, hexanes / EtOAc (gradient). The product enantiomers were separated by HPLC using a Reflect C- Amylose A column eluted with 60% hexanes / IPA. 1-(5-Amino-2,4-dichlorophenoxy)-3-(methyl(prop-2-yn-1-yl)amino) propan-2-ol

[0141] The ‘fast’ enantiomer eluted at 6.14 min. White solid.1H NMR (400 MHz, CD3OD) δ 7.14 (s, 1H), 6.54 (s, 1H), 4.07 (dq, J = 7.7, 4.7 Hz, 1H), 3.98 – 3.90 (m, 2H), 3.46 – 3.36 (m, 2H), 2.77 – 2.59 (m, 3H), 2.38 (s, 3H);13C NMR (151 MHz, CDCl3) δ 153.73, 142.42, 129.86, 112.25, 111.23, 101.48, 78.21, 73.41, 71.70, 66.43, 57.93, 46.20, 41.87; HRMS (+) (m / z): [M+H] calcd. for C13H17Cl2N2O2+: 303.0661; found: 303.0661. 1-(5-Amino-2,4-dichlorophenoxy)-3-(methyl(prop-2-yn-1-yl)amino) propan-2-ol

[0142] The ‘slow’ enantiomer eluted at 7.82 min. White solid.1H NMR (400 MHz, CD3OD) δ 7.14 (s, 1H), 6.54 (s, 1H), 4.07 (dq, J = 7.6, 4.9 Hz, 1H), 3.98 – 3.90 (m, 2H), 3.47 – 3.36 (m, 2H), 2.77 – 2.59 (m, 3H), 2.39 (s, 3H);13C NMR (151 MHz, CDCl3) δ 153.73, 142.42, 129.86, 112.26, 111.23, 101.48, 78.20, 73.42, 71.70, 66.43, 57.93, 46.20, 41.87; HRMS (+) (m / z): [M+H] calcd. for C13H17Cl2N2O2+: 303.0661; found: 303.0657.

[0143] Table 1 shows the compounds prepared in the present application.WSGR Docket No. 60661-704.601WSGR Docket No. 60661-704.601

[0144] Example 10. Biological Assays

[0145] Cell culture: Human prostate cancer cell lines, LNCaP and C4-2B, were obtained from ATCC and were authenticated by a short tandem repeat sequencing assay (GeneMarkerHID, SoftGenetics, LLC, State College, PA). LNCaP cells were cultured in RPMI1640 medium supplemented with 10% FBS and 1% Pen Strep antibiotics; and C4-2B cells were in T medium with 10% FBS and 1% Pen Strep antibiotics. Both cell lines were maintained at 37 °C under 5% CO2.

[0146] MAOA / B Enzyme Inhibition Assay: Inhibition of MAOA and MAOB enzymatic activity by synthesized compounds was determined using the MAO-GloTMAssay Kit (Promega). The experiments followed the manufacturer’s protocol and used 5 mg / mL of either human MAOA (Sigma-Aldrich M7316) or human MAOB (Sigma-Aldrich M7441). IC50 values were calculated for each test inhibitor using a custom-designed implementation of the drc package for R.

[0147] Cell proliferation analysis: The effects on cancer cell viability were measured using the CellTiter-Glo 3D Cell Viability Assay (Promega) following the manufacturer’s protocol. Briefly, cells were seeded in opaque-walled 96 well plates (Corning) in their appropriate media with a concentration of 5000 cells / well. Plates with the cells were kept at 37 °C in 5% CO2overnight, following by addition of test or control compounds on the next day. After incubation for 3 d 37°C under 5% CO2, all wells were treated with 100 μL mixture of CellTiter Glo 3D Reagent and DPBSWSGR Docket No. 60661-704.601 (1X) in 1:1 ratio and incubated at rt for 30 min on a plate shaker at 300 rpm. The colorimetric intensity of formazan was quantitated using BioTek’s microplate reader. Cell viability percentages and CC50values were calculated using a custom designed implementation of the drc package for R.

[0148] Statistical Analysis: Unless otherwise specified, all statistical tests were two-sided, conducted at a confidence level of alpha= 0.05, and performed using R.

[0149] Properties of synthesized derivatives, clorgyline, phenelzine, and selegeline are shown in Table 2. Table 2WSGR Docket No. 60661-704.601Molecular weight (MW), Rotatable bonds (RB), Molecular Volume (MV), Hydrogen Bond Donor (HBD), Hydrogen Bond Acceptor (HBA), Partition coefficient (logP), Solubility (logS), cell permeability kidney cells (PMDCK) Predicted ADME Characteristics and Computational Studies

[0150] In silico docking studies were conducted on a co-crystal structure of human MAOA and clorgyline (PDB: 2BXS) using ICM-Pro Molecular Modeling Software (Molsoft) version 3.9-2b. Clorgyline covalently binds to the flavin group of the flavin adenine dinucleotide (FAD) cofactor, thus each analogue was constructed accordingly then docked inside the binding pocket using the original clorgyline-FAD complex as a template (FAD is covalently bound to Cys406).

[0151] Predicted ADME properties were calculated for all derivatives using Schrödinger (release 2020-2) QikProp. QikProp provides ranges for comparing a particular molecule’s properties with those of 95% of known drugs. The following characteristics were optimized to localize the designed analogues to the peripheral circulation: a) predicted apparent Caco-2 cell permeability (cancer coli (CACO2)), b) central nervous system activity (CNS), c) predicted brain / blood partition coefficient (log BB), and d) predicted human oral absorption percent (% human oral absorption or % HOA) (Table 3). Predicted Caco values >25 are considered to passively transport across the gut-blood barrier. In addition, the predicted CNS activity relates to its ability to exert effects in the CNS. These values range from -2 (inactive) to +2 (active). Lastly, %HOA is predicted based on a quantitative multiple linear regression model where values greater than 80% are predicted to have high oral absorption and values below 25% have poor absorption. Table 3. Predicted ADME Characteristics for synthesized derivatives clorgyline, phenelzine, and selegeline.WSGR Docket No. 60661-704.601MAOA / MAOB enzyme inhibition and prostate cancer cell cytotoxicity assays

[0152] IC50 values for inhibition of MAOA and MAOB in vitro are compiled in Table 4 for all of the synthesized compounds, along with the values for clorgyline (MAOA specific inhibitor), selegeline (MAOB specific inhibitor), and phenelzine (non-specific MAOA / MAOB inhibitor). Table 4. Inhibition of MAOA and MAOB by the synthesized compounds, clorgyline, phenelzine, and selegeline.WSGR Docket No. 60661-704.601Cytotoxicity Assays

[0153] In Table 5, CC50values of the synthesized compounds, clorgyline, and phenelzine obtained in LNCaP and C42B human prostate cancer cell lines are shown. All values represent the average of at least two independent experiments. Table 5. Cancer Cell Cytotoxicity AssaysDiscussion Molecular docking and structure activity relationship (SAR) studies

[0154] A. Optimization of logBB with retained or enhanced hMAOA potency and selectivity.

[0155] A-1.5-Polar aryl modifications.

[0156] In the present application, modifications to the 2,4-dichlorophenyl moiety in clorgyline that would decrease logBB (by increasing polarity) while retaining or enhancing selectiveWSGR Docket No. 60661-704.601 hMAOA inhibition were made. Inspection of the clorgyline co-crystal structure suggested that addition of a HBD group to position 5 of the phenyl ring should enable a binding interaction with the carbonyl oxygen of Ser209in hMAOA. Indeed, compound 3a which has a 5-OH substituent and compound 3b which has a 5-NH2substituent were more potent inhibitors of hMAOA (24 and 16 nM, respectively) than clorgyline itself (64 nM), while having 3x lower predicted logBB values (0.29 and 0.24, respectively vs. 0.88 for clorgyline). Both compounds maintain selectivity in inhibiting hMAOA vs hMAOB (EC50 ratio >104). Consistent with the polarity / hydrogen bonding hypothesis, a non-polar hydrophobic 5-methyl group (compound 3c) resulted in a logBB similar to clorgyline but a hundredfold decrease in inhibition potency. Conversely, addition of the polar HBA cyano group (compound 3d) dramatically decreased the logBB group while having relatively little effect on hMAOA potency compared to clorgyline. Introduction of an acetoamido (compound 3e), formamido (compound 7), pyrazolcarboamido (compound 8) or sulfonamido (compound 9) at the carbon 5 position produced logBB values in the +0.2 to -0.4 range, yet all were significantly less potent inhibitors than clorgyine in the MAO-Glo assay. These substituents appear to clash with the limited space available in the binding pocket adjacent to the 5-phenyl, which can also explain the reduced activity of the 5-methyl derivative compound 3c. Notably, results of the CellTiter-Glo assay showed that compound 8 had comparable IC50values to that of compound 3b. Further analysis of compound 8 is required to identify if this compound is undergoing an enzymatic cleavage. Overall, the SAR results suggest that a single-atom hydrogen bond donor is a suitable modification at the 5-phenyl position of the scaffold, exemplified by compounds 3a and 3b. These derivatives have significantly lower predicted logBB values which also exhibiting increased hMAOA potency and equivalent or higher selectivity than that of clorgyline.

[0157] B. Additional polar modifications.

[0158] Having established the amine as a promising 5-phenyl substituent in the scaffold, two other sites for addition of a polar group to further lower the logBB were identified: a) the propargyl amine atom (position Z in Formula (I)) and the b) the interior propylene chain (position Y in Formula (I)) were examined.

[0159] B-1. Propargyl amine substitution.

[0160] Based on the docking analysis, the N-methyl was replaced with a 2-hydroxyethy group in both the aniline derivative (compound 3b) and clorgyline itself to form compound 13a and 13b, respectively. Both analogues have logBB values much lower than clorgyline (logBB of compound 13a is -0.4) but are 10x less potent in inhibiting hMAOA.

[0161] B-2. 2-Propylene substitution with a polar group.WSGR Docket No. 60661-704.601

[0162] The docking analysis suggested that introduction of a 2-hydroxy group with S stereochemistry in the propyl chain would enable a hydrogen bond with Glu216 in the binding site. The corresponding 3b analogue 15 was synthesized as a racemate, which were resolved by chiral HPLC into fast- and slow-eluting enantiomers. These were similar in inhibitory potency to clorgyline but were calculated to have logBB values of -0.2 as well as CNS scores of 0 (vs 2 for clorgyline). Despite the predicted preference for one enantiomer, both had similar EC50 values and CC50 values, so the averages are given in Tables 4 and 5. Cytotoxicity against LnCAP and C42B prostate cancer cells

[0163] The CC50of clorgyline was determined to be 51.5 μM in LnCAP cells and 53.5 μM in C42B cells. The cytotoxic effect was preserved in all of the clorgyline analogues. A general relationship was observed between potency in terms of enzyme inhibition and cytotoxicity such that compounds 3b and 9 exhibited among the lowest and highest IC50and CC50values, respectively. Conclusion

[0164] Using the co-crystal structure of clorgyline bound with FAD co-factor in the hMAOA active site as a reference, the present application discloses a synthesis of a series of compounds predicted to have lower CNS penetration (logBB). All synthesized derivatives displayed favorable drug-like characteristics, such as predicted Caco-2 permeability and human oral absorption, and highly selective hMAOA binding interactions. Introduction of a HBD group (NH2or OH) at position 5 of the phenyl ring resulted in 3x more potent hMAOA inhibition than clorgyline itself, with equivalent or better hMAOB selectivity, and similar prostate cancer cell cytotoxicity. In contrast, introduction of larger substituents at this position or at the terminal amine significantly reduced the hMAOA inhibition potency, which was attributed in part to a steric clash within the binding pocket of the MAOA active site. Replacement of the N-methyl group in compound 13 by a more polar but larger 2-hydroxyethyl group did not enhance potency. However, introduction of a polar 2-hydroxy in the propyl chain (compound 15) retained the highly selective MAOA inhibition and cancer cell cytotoxicity of clorgyline while reducing its CNS score from 2 to 0. This new class of peripherally directed MAOIs can allow safer therapeutic targeting of MAOA for a variety of anti-cancer indications.

[0165] Example 11. Studies to confirm low blood:brain penetration.

[0166] Uptake and accumulation of drugs into the brain can be modeled in laboratory studies. The blood-brain barrier (BBB) is a key factor which controls distribution of drugs into the brain which can be modeled in the laboratory using a variety of 2-chamber assays with a semi-permeable barrier between the chambers to functionally represent the BBB. One such assay is known as the parallel artificial membrane permeability assay (PAMPA) which utilizes a lipid extract deriveWSGR Docket No. 60661-704.601 from animal brain tissue to separate donor and acceptor wells in a 2-chamber assay. Other versions of 2-chamber assays utilize a cell-based barrier to create a version of the BBB using a variety of cell types such as endothelial cells, pericytes, and astrocytes to model the specialized tight junctions, transporters, and efflux pumps which maintain the BBB in vivo. For any of these 2-chamber assays, the test compound is introduced into a donor well at a known concentration and diffusion into an acceptor well is measured in a time dependent manner. This data is analyzed to compute parameters such as the apparent diffusion or partition coefficients for each of the test compounds. These 2-chamber assays are used to compare and empirically validate decreased penetration of the test compounds, such as those described in the examples herein, across the BBB.

[0167] Assays performed in living animals verify low brain penetration of the test compounds in vivo. First, we a tissue distribution study is performed in mice. Animals are given a single dose of the test compound, such as any of the test compounds described in the examples herein, (via intravenous, intraperitoneal, or oral routes) followed by euthanasia at defined time points. Distribution of the test compound in brain, blood, and other tissues is directly measured to estimate key pharmacokinetic parameters in humans. Next, behavioral assays are used to explore acute brain and neurocognitive effects of the test compounds in living animals. Specifically, the forced swim and tail suspension tests are used to measure effects of test compounds on the duration of immobility and latency which are taken as objective measures of their effect on mood and stress behaviors. Together, these approaches confirm that the test compounds avoid the brain penetration and potential for mood and behavior effects observed with antidepressants.

[0168] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

Claims

WSGR Docket No. 60661-704.601 CLAIMS What is claimed is:

1. A compound, or pharmaceutically acceptable salt or solvate thereof, or a stereoisomer or mixture of stereoisomers thereof, having the structure of Formula (I):Formula (I) wherein: * denotes R- or S- stereoisomer, or a racemate thereof; R1is hydrogen, -OH,1a-SR , - OPO3(R1a)(R1b), C1-12alkyl, C1-12hydroxyalkyl, or C1-12haloalkyl; R2is C1-6alkyl, wherein the C1-6alkyl is optionally substituted with -OH, -NH2, -SH, - NHOH, -NHNH2or -O-C1-6alkyl; R3is hydrogen, -OH, or -O-C1-6alkyl; R1ais hydrogen, -OH, -NH2, C1-6alkyl, C2-6alkenyl or C2-6alkynyl; and R1bis hydrogen, -OH, -NH2, -CO-C1-6alkyl, -SO2-C1-6alkyl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-12cycloalkyl, C3-12aryl, 3- to 10- membered heterocyclyl, or 3- to 10- membered heteroaryl, wherein when R1is hydrogen, and R3is H, R2is not methyl.

2. The compound of claim 1, wherein R1is hydrogen, -OH, -CN, -N(R1a)(R1b), -NHC(=O)R1b, - C(=O)R1a, C1-12alkyl, C1-12hydroxyalkyl, or C1-12haloalkyl.

3. The compound of claim 1 or 2, wherein R1is hydrogen, -OH, -CN, -N(R1a)(R1b), - NHC(=O)R1b, -C(=O)R1a, or C1-6hydroxyalkyl.

4. The compound of any one of claims 1 to 3, wherein R1ais hydrogen, -OH, -NH2, or C1-6alkyl.

5. The compound of any one of claims 1 to 4, wherein R1ais hydrogen or -OH.

6. The compound of any one of claims 1 to 5, wherein R1bis hydrogen, -CO-C1-6alkyl, -SO2-C1-6alkyl, C1-6alkyl, C3-12cycloalkyl, C3-12aryl, 3- to 10- membered heterocyclyl, or 3- to 10- membered heteroaryl.

7. The compound of any one of claims 1 to 6, wherein R1bis hydrogen, C1-3 alkyl, -CO-C1-3 alkyl, -SO2-C1-3alkyl, or 3- to 10- membered heteroaryl.

8. The compound of any one of claims 1 to 7, wherein R1is H, -OH, -CN, -CH3, -NH2,- NHC(=O)H, -NHC(=O)CH3, -NHSO2CH3, or -NHC(=O)-pyrazolyl.

9. The compound of any one of claims 1 to 8, wherein R2is C1-3alkyl, wherein the C1-3alkyl is optionally substituted with -OH, -NH2, -SH, -NHOH, or -NHNH2.WSGR Docket No. 60661-704.601 10. The compound of any one of claims 1 to 9, wherein R2is methyl or -CH2CH2OH.

11. The compound of any one of claims 1 to 10, wherein R3is hydrogen or -OH.

12. The compound of any one of claims 1 to 11, wherein the compound is: , , , ,13. A pharmaceutical composition comprising a compound, or pharmaceutically acceptable salt or solvate thereof, of any one of claims 1 to 12, and a pharmaceutically acceptable excipient.

14. A method of treating cancer in a patient in need thereof, comprising administering to the patient the compound of any one of claims 1 to 12, or pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition of claim 13.

15. The method of claim 14, wherein the compound has reduced penetration across the blood- brain barrier as compared to clorgyline using a biodistribution assay.

16. The method of claim 14 or 15, wherein the compound has a logBB value of less than 0.

4.

17. The method of any one of claims 14 to 16, wherein the compound is a monoamine oxidase inhibitor (MAOI).

18. The method of claim 17, wherein the MAOI is a MAOA inhibitor.

19. The method of claim 17, wherein the MAOI is a MAOB inhibitor.

20. The method of any one of claims 14 to 19, wherein the cancer is prostate cancer.WSGR Docket No. 60661-704.601 21. The method of any one of claims 14 to 20, wherein the cancer is metastatic prostate cancer.

22. The method of any one of claims 14 to 21, wherein the patient is resistant to another antineoplastic treatment.

23. A method of inhibiting monoamine oxidase (MAO), the method comprising administering the compound of any one of claims 1 to 12, or a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition of claim 13, to a patient in need thereof, thereby inhibiting MAO.

24. The method of claim 23, wherein the MAO is monoamine oxidase A (MAOA).

25. The method of claim 23, wherein the MAO is monoamine oxidase B (MAOB).

26. The method of any one of claims 23 to 25, wherein the patient has cancer, and inhibition of MAO treats the cancer.

27. The method of claim 26, wherein the cancer is prostate cancer.

28. The method of claim 26 or 27, wherein the cancer is metastatic prostate cancer.

29. The method of any one of claims 23 to 28, wherein the compound has reduced penetration across the blood-brain barrier as compared to clorgyline using the biodistribution assay.

30. The method of any one of claims 23 to 29, wherein the compound has a logBB value of less than 0.4.